Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
'We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products,' said Dennis McGrath, Lucid's Chief Financial Officer. 'This important milestone is a testament to the significant progress Lucid has made in enhancing shareholder value over the past year. We are confident that it will increase our visibility and access to a broader range of institutional investors.'
The broad-market Russell 3000 Index includes the largest 3,000 U.S. public companies by market capitalization. The Russell 2000 Index is a subset of the broader Russell 3000 Index limited to small-cap companies. The indexes are reconstituted annually by re-ranking companies based on total market capitalization as of the reconstitution rank date, which was April 30, 2025, this year. Index membership remains in place for one year and results in automatic inclusion in the relevant growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to FTSE Russell, approximately $10.6 trillion in assets are benchmarked against the Russell U.S. Indexes.
For more information on the Russell 2000® and Russell 3000® Indexes and the Russell indexes reconstitution, visit the 'Russell Reconstitution' section on the FTSE Russell website.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
About FTSE Russell
FTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, 'Risk Factors,' in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, 'Risk Factors' in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia: https://www.prnewswire.com/news-releases/lucid-diagnostics-to-join-russell-2000-and-russell-3000-indexes-302465481.html
SOURCE Lucid Diagnostics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Tennessee readies for execution of man with working implanted defibrillator
NASHVILLE, Tenn. (AP) — Tennessee is gearing up for an execution on Tuesday that experts say would likely mark the first time a man has been put to death with a working defibrillator in his chest. Gov. Bill Lee declined Monday to grant a reprieve, clearing the way for Byron Black's execution after a legal battle and ongoing uncertainty about whether the implantable cardioverter-defibrillator will shock his heart when the lethal drug takes effect. The nonprofit Death Penalty Information Center said it's unaware of any other cases in which a person on death row made similar claims to Black's about defibrillators or pacemakers. Black's attorneys said they haven't found a comparable case, either. Lee said the courts have "universally determined that it is lawful to carry out the jury's sentence of execution given to Mr. Black for the heinous murders of Angela Clay and her daughters Lakeisha, age 6, and Latoya, age 9." The U.S. Supreme Court on Monday rejected Black's appeals. The execution would be Tennessee's second since May, after a pause for five years, first because of COVID-19 and then because of missteps by state corrections officials. Twenty-seven men have died by court-ordered execution so far this year in the U.S., and nine other people are scheduled to be put to death in seven states during the remainder of 2025. The number of executions this year exceeds the 25 carried out last year and in 2018. It is the highest total since 2015, when 28 people were put to death. Black's condition Black, 69, is in a wheelchair, and he has dementia, brain damage, kidney failure, congestive heart failure and other conditions, his attorneys have said. The implantable cardioverter-defibrillator he has is a small, battery-powered electronic device that is surgically implanted in the chest. It serves as a pacemaker and an emergency defibrillator. Black's attorneys say in order to be sure it's off, a doctor must place a programming device over the implant site, sending it a deactivation command, with no surgery required. In mid-July, a trial court judge agreed with Black's attorneys that officials must have his device deactivated to avert the risk that it could cause unnecessary pain and prolong the execution. But the state Supreme Court intervened July 31 to overturn that decision, saying the other judge lacked the authority to order the change. The state has disputed that the lethal injection would cause Black's defibrillator to shock him. Even if shocks were triggered, Black wouldn't feel them, the state said. Black's attorneys have countered that even if the lethal drug being used, pentobarbital, renders someone unresponsive, they aren't necessarily unaware or unable to feel pain. Kelley Henry, Black's attorney, said the execution could become a 'grotesque spectacle.' The legal case also spurred a reminder that most medical professionals consider participation in executions a violation of health care ethics. Black's case Black was convicted in the 1988 shooting deaths of his girlfriend Angela Clay, 29, and her two daughters. Prosecutors said he was in a jealous rage when he shot the three at their home. At the time, Black was on work-release while serving time for shooting Clay's estranged husband. Linette Bell, whose sister and two nieces were killed, recently told WKRN-TV: 'He didn't have mercy on them, so why should we have mercy on him?' Intellectual disability claim In recent years, Black's legal team has unsuccessfully tried to get a new hearing over whether he is intellectually disabled and ineligible for the death penalty under U.S. Supreme Court precedent. His attorneys have said that if they had delayed a prior attempt to seek his intellectual disability claim, he would have been spared under a 2021 state law. Nashville District Attorney Glenn Funk contended in 2022 that Black is intellectually disabled and deserved a hearing under that 2021 law, but the judge denied it. That is because the 2021 law denies a hearing to people on death row who have already filed a similar request and a court has ruled on it 'on the merits." In Funk's attempt, he focused on input from an expert for the state in 2004 who determined back then that Black didn't meet the criteria for what was then called "mental retardation.' But she concluded that Black met the new law's criteria for a diagnosis of intellectual disability. Black also sought a determination by the courts that he is incompetent to be executed.
Yahoo
10 minutes ago
- Yahoo
Guardians reliever Nic Enright, battling lymphoma, earns emotional first save
NEW YORK (AP) — The first career save for Nic Enright was a particularly meaningful one. Enright, who was diagnosed with Hodgkin lymphoma in late 2022 and is scheduled to complete his treatments later this year, allowed an unearned run in the 10th inning Monday night to close out the Cleveland Guardians' 7-6 win over the New York Mets. 'He was almost crying on the field just now,' Guardians manager Stephen Vogt said. 'If you read his story, it's pretty inspirational.' Cleveland selected Enright in the 20th round of the 2019 amateur draft out of Virginia Tech. He received his diagnosis Dec. 22, 2022 — 15 days after the Miami Marlins took him in the Rule 5 draft. After four rounds of immunotherapy in early 2023, Enright made nine minor league rehab appearances for the Marlins before being designated for assignment and returning to the Guardians in late May. He missed most of last season due to a right shoulder strain, but went 2-1 with a 1.06 ERA in 16 appearances with Triple-A Columbus. The right-hander has one more round of cancer treatment scheduled for November. 'I made the decision when I was diagnosed in 2022 with Hodgkin lymphoma that I wasn't going to let that define my life and dictate how I was going to go about my life,' Enright said. 'It's something where, for anyone else who is going through anything similar, (it shows) I haven't just holed up in my house and felt sorry for myself this whole time.' Enright made his major league debut May 25 and has a 2.01 ERA in 19 appearances for the Guardians, whose bullpen is in flux with All-Star closer Emmanuel Clase on paid leave as part of a sports gambling investigation. Hunter Gaddis and Cade Smith pitched the eighth and ninth innings Monday before Enright entered with a two-run lead. He gave up a two-out RBI single to Brett Baty before retiring Luis Torrens on a fly out to the warning track in right. 'I definitely held my breath as I saw Nolan (Jones) kind of keep running,' Enright said. 'But I had faith. As he kind of got closer to the wall, I realized it was losing steam.' Enright was showered with beer by teammates in the locker room. 'I was so happy, oh, I was going nuts in here,' Guardians starting pitcher Slade Cecconi said with a smile. 'I was going absolutely berserk. He came in running up the stairs, smile on his face.' Enright thanked his wife, his parents and the rest of his family for their support throughout an interview at his locker. He got the ball from the final out and plans to set aside his uniform and hat as well as a lineup card. 'Really, really cool,' Enright said. 'These last couple of years, especially, I've gone through a lot of adversity and just everything that's gone on. And so for me, it's being able to reflect on those in these moments. I think that helps being able to slow the game down. Because it hasn't exactly been a red-carpet rollout for my career trajectory.' ___ AP MLB:
Yahoo
10 minutes ago
- Yahoo
In rejecting the jobs report, Trump follows his own playbook of discrediting unfavorable data
WASHINGTON (AP) — When the coronavirus surged during President Donald Trump's first term, he called for a simple fix: Limit the amount of testing so the deadly outbreak looked less severe. When he lost the 2020 election, he had a ready-made reason: The vote count was fraudulent. And on Friday, when the July jobs report revisions showed a distressed economy, Trump had an answer: He fired the official in charge of the data and called the report of a sharp slowdown in hiring 'phony.' Trump has a go-to playbook if the numbers reveal uncomfortable realities, and that's to discredit or conceal the figures and to attack the messenger — all of which can hurt the president's efforts to convince the world that America is getting stronger. 'Our democratic system and the strength of our private economy depend on the honest flow of information about our economy, our government and our society,' said Douglas Elmendorf, a Harvard University professor who was formerly director of the Congressional Budget Office. 'The Trump administration is trying to suppress honest analysis.' The president's strategy carries significant risks for his own administration and a broader economy that depends on politics-free data. His denouncements threaten to lower trust in government and erode public accountability, and any manipulation of federal data could result in policy choices made on faulty numbers, causing larger problems for both the president and the country. The White House disputes any claims that Trump wants to hide numbers that undermine his preferred narratives. It emphasized that Goldman Sachs found that the two-month revisions on the jobs report were the largest since 1968, outside of a recession, and that should be a source of concern regarding the integrity of the data. Trump's aides say their fundamental focus is ensuring that any data gives an accurate view of reality. Not the first time Trump has sought to play with numbers Trump has a long history of dismissing data when it reflects poorly on him and extolling or even fabricating more favorable numbers, a pattern that includes his net worth, his family business, election results and government figures: — Judge Arthur Engoron ruled in a lawsuit brought by the state of New York that Trump and his company deceived banks, insurers and others by massively overvaluing his assets and exaggerating his net worth on paperwork used in making deals and securing loans. — Trump has claimed that the 2016 and 2020 presidential elections were each rigged. Trump won the 2016 presidential election by clinching the Electoral College, but he lost the popular vote to Hillary Clinton, a sore spot that led him to falsely claim that millions of immigrants living in the country illegally had cast ballots. He lost the 2020 election to Joe Biden but falsely claimed he had won it, despite multiple lawsuits failing to prove his case. — In 2019, as Hurricane Dorian neared the East Coast, Trump warned Alabama that the storm was coming its way. Forecasters pushed back, saying Alabama was not at risk. Trump later displayed a map in the Oval Office that had been altered with a black Sharpie — his signature pen — to include Alabama in the potential path of the storm. — Trump's administration has stopped posting reports on climate change, canceled studies on vaccine access and removed data on gender identity from government sites. — As pandemic deaths mounted, Trump suggested that there should be less testing. 'When you do testing to that extent, you're going to find more people,' Trump said at a June 2020 rally in Oklahoma. 'You're going to find more cases. So I said to my people, 'Slow the testing down, please.'' While Trump's actions have drawn outcry from economists, scientists and public interest groups, Elmendorf noted that Trump's actions regarding economic data could be tempered by Congress, which could put limits on Trump by whom he chooses to lead federal agencies, for example. 'Outside observers can only do so much," Elmendorf said. 'The power to push back against the president rests with the Congress. They have not exercised that power, but they could.' White House says having its own people in place will make data 'more reliable' Kevin Hassett, director of the White House National Economic Council, took aim at the size of the downward revisions in the jobs report (a combined 258,000 reduction in May and June) to suggest that the report had credibility issues. He said Trump is focused on getting dependable numbers, despite the president linking the issue to politics by claiming the revisions were meant to make Republicans look bad. 'The president wants his own people there so that when we see the numbers, they're more transparent and more reliable,' Hassett said Sunday on NBC News. Jed Kolko, a senior fellow at the Peterson Institute for International Economics who oversaw the Census Bureau and Bureau of Economic Analysis during the Biden administration, stressed that revisions to the jobs data are standard. That's because the numbers are published monthly, but not all surveys used are returned quickly enough to be in the initial publishing of the jobs report. 'Revisions solve the tension between timeliness and accuracy,' Kolko said. 'We want timely data because policymakers and businesses and investors need to make decisions with the best data that's available, but we also want accuracy.' Kolko stressed the importance in ensuring that federal statistics are trustworthy not just for government policymakers but for the companies trying to gauge the overall direction of the economy when making hiring and investment choices. 'Businesses are less likely to make investments if they can't trust data about how the economy is doing,' he said. Not every part of the jobs report was deemed suspect by the Trump administration. Before Trump ordered the firing of the Bureau of Labor Statistics commissioner, Erika McEntarfer, the White House rapid response social media account reposted a statement by Vice President JD Vance noting that native-born citizens were getting jobs and immigrants were not, drawing from data in the household tables in the jobs report. Labor Secretary Lori Chavez-DeRemer also trumpeted the findings on native-born citizens, noting on Fox Business Network's 'Varney & Co.' that they are accounting "for all of the job growth, and that's key.' During his first run for the presidency, Trump criticized the economic data as being fake only to fully embrace the positive numbers shortly after he first entered the White House in 2017. White House says transparency is a value The challenge of reliable data goes beyond economic figures to basic information on climate change and scientific research. In July, taxpayer-funded reports on the problems climate change is creating for America and its population disappeared from government websites. The White House initially said NASA would post the reports in compliance with a 1990 law, but the agency later said it would not because any legal obligations were already met by having reports submitted to Congress. The White House maintains that it has operated with complete openness, posting a picture of Trump on Monday on social media with the caption, 'The Most Transparent President in History.' In the picture, Trump had his back to the camera and was covered in shadows, visibly blocking out most of the light in front of him. ___ Associated Press writer Michelle Price in Washington contributed to this report. Josh Boak, The Associated Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
